Abstract | PURPOSE: PATIENTS AND METHODS: A two-stage design was implemented in a phase II study involving 47 patients with bulky mediastinal stage I/II or stage III/IV Hodgkin's disease. Twelve weeks of the Stanford V chemotherapy regimen were given with consolidative radiotherapy (36 Gy) to lymph nodes >/= 5 cm and/or macroscopic splenic disease. Treatment was administered in one of five institutions participating in the Eastern Cooperative Oncology Group. RESULTS: With a median follow-up of 4.8 years, 45 patients are alive and 40 have been continuously disease-free. The estimated freedom from progression was 87% at 2 years and 85% at 5 years. Overall survival was 96% at 2 and 5 years. There was one death from Hodgkin's disease and one death from an M5 acute leukemia. Six of seven relapsed patients received high-dose therapy and autologous stem-cell transplantation. The freedom from second progression for the seven relapsed patients was estimated at 98% at 3 years. CONCLUSION:
|
Authors | S J Horning, J Williams, N L Bartlett, J M Bennett, R T Hoppe, D Neuberg, P Cassileth |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 18
Issue 5
Pg. 972-80
(Mar 2000)
ISSN: 0732-183X [Print] United States |
PMID | 10694546
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Combined Modality Therapy
- Feasibility Studies
- Female
- Follow-Up Studies
- Hodgkin Disease
(drug therapy, mortality, radiotherapy, therapy)
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Quality Control
- Survival Analysis
- Treatment Outcome
|